{"id":"mercaptopurine-imatinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Fluid retention (imatinib-related)"},{"rate":null,"effect":"Muscle cramps (imatinib-related)"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:25:38.288700","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mercaptopurine is a thiopurine antimetabolite that interferes with purine metabolism and DNA synthesis, making it effective against leukemias and lymphomas. Imatinib selectively inhibits the BCR-ABL tyrosine kinase fusion protein characteristic of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), as well as other kinases like c-KIT and PDGFR. The combination targets both the metabolic vulnerability and the specific oncogenic driver mutations in leukemic cells.","oneSentence":"Mercaptopurine and imatinib work together as a combination therapy: mercaptopurine is a purine analog that inhibits nucleotide synthesis to kill rapidly dividing cells, while imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:50.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)"},{"name":"Chronic myeloid leukemia (CML)"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT06175702","phase":"","title":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-12-25","conditions":"Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL","enrollment":150},{"nctId":"NCT00002514","phase":"PHASE3","title":"Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-07","conditions":"Leukemia","enrollment":1929},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT00061945","phase":"PHASE1, PHASE2","title":"Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-06","conditions":"Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia","enrollment":302},{"nctId":"NCT00137111","phase":"PHASE3","title":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2000-07-08","conditions":"Lymphoblastic Leukemia, Acute","enrollment":501},{"nctId":"NCT02611492","phase":"PHASE3","title":"A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04","conditions":"Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia","enrollment":265},{"nctId":"NCT00458848","phase":"PHASE2","title":"Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2004-10","conditions":"Leukemia","enrollment":470},{"nctId":"NCT01429610","phase":"PHASE2","title":"Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2011-11","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":78},{"nctId":"NCT00973752","phase":"PHASE2","title":"Treatment of Older Adults With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-08","conditions":"Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT02894645","phase":"PHASE4","title":"Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2008-10","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":500},{"nctId":"NCT00022737","phase":"PHASE3","title":"Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT01005758","phase":"PHASE2","title":"Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2009-01","conditions":"Leukemia","enrollment":180},{"nctId":"NCT01665001","phase":"PHASE2","title":"Personalized Therapy of Precursor Lymphoid Neoplasms","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice","startDate":"2012-08","conditions":"Precursor Lymphoid Neoplasms","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mercaptopurine, Imatinib","genericName":"Mercaptopurine, Imatinib","companyName":"St. Jude Children's Research Hospital","companyId":"st-jude-children-s-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mercaptopurine and imatinib work together as a combination therapy: mercaptopurine is a purine analog that inhibits nucleotide synthesis to kill rapidly dividing cells, while imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases. Used for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), Chronic myeloid leukemia (CML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}